首页> 美国卫生研究院文献>Stem Cells Translational Medicine >Concise Review: Animal Substance-Free Human Embryonic Stem Cells Aiming at Clinical Applications
【2h】

Concise Review: Animal Substance-Free Human Embryonic Stem Cells Aiming at Clinical Applications

机译:简洁评论:旨在临床应用的无动物物质人类胚胎干细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human embryonic stem cells have been considered the gold standard as a cell source for regenerative medicine since they were first cultured in 1998. They are pluripotent and can form principally all the cells types in the body. They are obtained from supernumerary human in vitro fertilization embryos that cannot be used for infertility treatment. Following studies on factors regulating pluripotency and differentiation, we now have techniques to establish and effectively expand these cells in animal substance-free conditions, even from single cells biopsied from eight-cell stage embryos in chemically defined feeder-free cultures. The genetic stability and absence of tumorigenic mutations can be determined. There are satisfactory animal tests for functionality and safety. The first clinical trials are ongoing for two indications: age-related macular degeneration and spinal cord injury.
机译:自从1998年首次培养以来,人类胚胎干细胞就被认为是再生医学的细胞来源的金标准。它们具有多能性,并且可以在体内形成所有类型的细胞。它们是从无法用于不育治疗的人类体外受精胚胎中获得的。在对调节多能性和分化的因素进行研究之后,我们现在拥有在无动物物质条件下建立和有效扩增这些细胞的技术,甚至包括在化学定义的无饲养层培养物中从八细胞阶段胚胎活检的单细胞。可以确定遗传稳定性和无致癌突变。对于功能和安全性,有令人满意的动物测试。正在进行两个症状的首次临床试验:年龄相关性黄斑变性和脊髓损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号